In Silico Investigation of Quinoxaline Derivatives as EGFR Kinase Inhibitor Candidates
European Multidisciplinary Journal of Modern Science · 30.10.2026 · 28 (4) · 320-331
DOI: 10.51699/m4xd0382 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Multidisciplinary Journal of Modern Science, online erschienen am 30.10.2026. Verfasst von Sajjad Ali Kadhim. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer ranks among the leading causes of death worldwide and epidermal growth factor receptor (EGFR) is a validated drug target for non-small cell lung cancer (NSCLC). These conventional drugs fail to effectively discriminate between diseased and healthy cells. While osimertinib is an example of a third-generation EGFR inhibitor and multiple quinoxalines are known to exhibit a variety of documented pharmacological effects, the potential of these compounds to engage EGFR kinase has not been studied before. The study aimed to design fifteen quinoxaline compounds as potential inhibitors of EGFR and computationally evaluate their binding affinity (BA), as compared with the reference drug-osimertinib. I built the crystal structure of wild type EGFR kinase (9BY6) for molecular docking. To obtain a reference standard, I ran simulations of the binding of the drug Osimertinib and of the co-crystallized ligand to the protein under exactly the same conditions and used PLIP tool to analyze interactions between best and worst performing molecules against this reference drug. All 15 derivatives indicated a binding affinity of -7.853 -9.136 kcal/mol which showing more favorable predicted binding affinities than osimertinib (-7.627 kcal/mol). The strongest result was observed by the compound 15 binding to hydrogen bonding to CYS797 and also multiple hydrophobic bonds. Leucine 718 (LEU718) has been found to be the frequently interacting residue among the majority of quinoxaline- and Osimertinib-derived complexes, suggesting that it is a key member in the correlation pocket. The quinoxaline scaffold has validated as a promising beginning point for developing future (EGFR) inhibitors, predicting compound 15 to have a superior docking affinity than the reference inhibitor in this model. The results warrant greater experimental examination.
Zitieren
APA
Kadhim, S. A. (2026). In Silico Investigation of Quinoxaline Derivatives as EGFR Kinase Inhibitor Candidates. European Multidisciplinary Journal of Modern Science, 28(4), 320-331. https://doi.org/10.51699/m4xd0382
Vancouver
Kadhim SA. In Silico Investigation of Quinoxaline Derivatives as EGFR Kinase Inhibitor Candidates. European Multidisciplinary Journal of Modern Science. 2026;28(4):320-331. doi:10.51699/m4xd0382
BibTeX
@article{Kadhim2026,
author = {Kadhim, Sajjad Ali},
title = {In Silico Investigation of Quinoxaline Derivatives as EGFR Kinase Inhibitor Candidates},
journal = {European Multidisciplinary Journal of Modern Science},
year = {2026},
volume = {28},
number = {4},
pages = {320--331},
doi = {10.51699/m4xd0382}
}
EUVIMED